Search

Your search keyword '"Machineni S"' showing total 41 results

Search Constraints

Start Over You searched for: Author "Machineni S" Remove constraint Author: "Machineni S"
41 results on '"Machineni S"'

Search Results

1. Cardiovascular Outcomes in GRADE (Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study)

2. Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort

4. P2471A randomised, placebo-controlled trial of the effects of IV serelaxin on myocardial blood flow and vascular function in patients with stable coronary artery disease (CAD)

5. Individual kidney glomerular filtration rate in the interpretation of non-diagnostic curves on captopril renography

9. Concordance With Screening and Treatment Guidelines for Chronic Kidney Disease in Type 2 Diabetes.

11. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial.

12. Evaluation of weight change and cardiometabolic risk factors in a real-world population of US adults with overweight or obesity.

13. Impact of a Community-Based Weight Management Program in a North Carolina Health Care System.

15. Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.

17. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.

18. Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.

19. Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial.

20. Refractory Hypocalcemia Following Stomach Intestinal Pylorus-Sparing Bariatric Surgery and Thyroidectomy: Successful Management With Creation of a Proximal Roux-en-Y Gastric Bypass.

21. Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251).

22. Effect of a virtual self-management intervention for atrial fibrillation during the outbreak of COVID-19.

23. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.

24. Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial.

25. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.

26. Weight History in Clinical Practice: The State of the Science and Future Directions.

27. A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers.

28. Obesity Coverage on Medical Licensing Examinations in the United States. What Is Being Tested?

29. Pharmacokinetics of Glycopyrronium Following Repeated Once-Daily Inhalation in Healthy Chinese Subjects.

30. Randomized, Open-Label Study of the Pharmacokinetics and Safety of Oral and Intravenous Administration of Omadacycline to Healthy Subjects.

31. Lung Delivery of Indacaterol and Mometasone Furoate Following Inhalation of QMF149 in Healthy Volunteers.

32. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.

33. Pharmacokinetics of serelaxin in patients with severe renal impairment or end-stage renal disease requiring hemodialysis: A single-dose, open-label, parallel-group study.

34. Weight Loss After RYGB Is Independent of and Complementary to Serotonin 2C Receptor Signaling in Male Mice.

35. In Vitro-In Vivo Correlations Observed With Indacaterol-Based Formulations Delivered with the Breezhaler®.

36. Safety and tolerability of serelaxin, a recombinant human relaxin-2 in development for the treatment of acute heart failure, in healthy Japanese volunteers and a comparison of pharmacokinetics and pharmacodynamics in healthy Japanese and Caucasian populations.

37. Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine.

38. Conserved shifts in the gut microbiota due to gastric bypass reduce host weight and adiposity.

39. Superior appetite hormone profile after equivalent weight loss by gastric bypass compared to gastric banding.

40. Weight loss and incretin responsiveness improve glucose control independently after gastric bypass surgery.

Catalog

Books, media, physical & digital resources